Advertisement
Singapore markets closed
  • Straits Times Index

    3,287.75
    -5.38 (-0.16%)
     
  • S&P 500

    4,997.44
    -74.19 (-1.46%)
     
  • Dow

    37,796.48
    -664.44 (-1.73%)
     
  • Nasdaq

    15,405.31
    -307.44 (-1.96%)
     
  • Bitcoin USD

    63,353.33
    -2,632.41 (-3.99%)
     
  • CMC Crypto 200

    1,371.39
    -11.18 (-0.81%)
     
  • FTSE 100

    8,054.04
    +13.66 (+0.17%)
     
  • Gold

    2,332.50
    -5.90 (-0.25%)
     
  • Crude Oil

    82.44
    -0.37 (-0.45%)
     
  • 10-Yr Bond

    4.7230
    +0.0710 (+1.53%)
     
  • Nikkei

    37,628.48
    -831.60 (-2.16%)
     
  • Hang Seng

    17,284.54
    +83.27 (+0.48%)
     
  • FTSE Bursa Malaysia

    1,569.25
    -2.23 (-0.14%)
     
  • Jakarta Composite Index

    7,155.29
    -19.24 (-0.27%)
     
  • PSE Index

    6,574.88
    +2.13 (+0.03%)
     

Eli Lilly Initiates New Trial for Taltz in Plaque Psoriasis

Eli Lilly Initiates New Trial for Taltz in Plaque Psoriasis

Eli Lilly (LLY) announced in a press release on September 10 that the company has initiated the IXORA-R head-to-head (or H2H) study evaluating the superiority of drugs Taltz (ixekizumab) and Tremfya (guselkumab) in patients with moderate-to-severe plaque psoriasis. The below chart shows key highlights for the IXORA-R H2H trial.